Format

Send to

Choose Destination
Biochem Pharmacol. 2016 May 1;107:14-28. doi: 10.1016/j.bcp.2016.02.007. Epub 2016 Feb 17.

Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen.

Author information

1
Facultad de Medicina, Universidad Católica de Valencia, C/Quevedo 2, 46001 Valencia, Spain.
2
Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, 28220 Majadahonda, Spain.
3
Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, 28220 Majadahonda, Spain; Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
4
Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2, 28220 Majadahonda, Spain. Electronic address: ppalcami@isciii.es.
5
Facultad de Medicina, Universidad Católica de Valencia, C/Quevedo 2, 46001 Valencia, Spain. Electronic address: jose.gallego@ucv.es.

Abstract

New antiretroviral agents with alternative mechanisms are needed to complement the combination therapies used to treat HIV-1 infections. Here we report the identification of bioavailable molecules that interfere with the gene expression processes of HIV-1. The compounds were detected by screening a small library of FDA-approved drugs with an assay based on measuring the displacement of Rev, and essential virus-encoded protein, from its high-affinity RNA binding site. The antiretroviral activity of two hits was based on interference with post-integration steps of the HIV-1 cycle. Both hits inhibited RRE-Rev complex formation in vitro, and blocked LTR-dependent gene expression and viral transcription in cellular assays. The best compound altered the splicing pattern of HIV-1 transcripts in a manner consistent with Rev inhibition. This mechanism of action is different from those used by current antiretroviral agents. The screening hits recognized the Rev binding site in the viral RNA, and the best compound did so with substantial selectivity, allowing the identification of a new RNA-binding scaffold. These results may be used for developing novel antiretroviral drugs.

KEYWORDS:

Ciprofloxacin (PubChem CID: 2764); Clomiphene (PubChem CID: 1548953); Cyproheptadine (PubChem CID: 2913); Homochlorcyclizine (PubChem CID: 3627); Human immunodeficiency virus type 1; Mitoxantrone (PubChem CID: 4212); Neamine (PubChem CID: 72392); Neomycin B (PubChem CID: 8378); RNA; Rev; Screen; Transcription

PMID:
26896646
DOI:
10.1016/j.bcp.2016.02.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center